P1, N=10, Active, not recruiting, M.D. Anderson Cancer Center | Suspended --> Active, not recruiting

EA alleviates psoriasiform dermatitis by restoring keratinocyte homeostasis, suppressing immune cell infiltration and NET formation, suggesting its potential as a therapeutic agent derived from TCM.

The combination of IMQ with HDR brachytherapy induces a synergistic effect, improving the therapeutic antitumor effect of brachytherapy. Our data indicate that it is reasonable to use drugs that prevent changes in the TME in combination with radiotherapy.

Moreover, pathological changes induced by strenuous exercise were observed in the enthesis, including angiogenesis and upregulated expression of TNF-α and MMP-13. This study revealed that strenuous exercise exacerbates pathological changes in IMQ-induced psoriasis model mice.

Toward that end, we engineered BIO-GEM, a hierarchically structured biomimetic lymph node (bLN) platform comprising genipin-crosslinked gelatin microspheres (GEM) encapsulating deformable albumin-hitchhiking nanoemulsions (BIO, generated with bovine albumin, imiquimod adjuvant, and OVA antigen)...In multiple B16 murine melanoma models, BIO-GEM significantly suppressed tumor growth and extended the survival of mice. Intradermal vaccination was more efficacious than subcutaneous or intramuscular injection routes.

Isolinderalactone exhibits anti-inflammatory activity through multiple mechanisms, highlighting the potential of topical Isolinderalactone therapy for mild-to-moderate psoriasis.

P1, N=106, Recruiting, MonTa Biosciences ApS | N=69 --> 106 | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Mar 2027

The validation confirmed that this model is capable of directly detecting Poly(I:C) -induced transient IFNγ, enhancing intratumoral IFNγ signals upon anti-PD-1/CTLA-4 therapy, and dynamically tracking IFNγ expression during imiquimod-induced psoriasis. This transgenic mouse model provides a powerful tool for non-invasive, longitudinal tracking of IFNγ-expressing cells, offering novel insights into IFNγ-mediated immune regulation in inflammation and cancer. It holds promise for identifying IFNγ-related therapeutic targets and predicting responses to immunotherapies.

Non-surgical modalities-including photodynamic therapy, topical imiquimod, radiotherapy and, in advanced disease, systemic chemotherapy, HER2 targeted agents and immune checkpoint inhibitors-provide additional options in selected patients. A multidisciplinary, biomarker driven approach is essential to individualize management and improve long-term outcomes in this challenging disease.

P1/2, N=320, Active, not recruiting, Ascendis Pharma Oncology Division A/S | Recruiting --> Active, not recruiting

P1/2, N=75, Recruiting, SURGE Therapeutics | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> May 2026

Our findings indicate that Grg3 confers protective effects in a murine model of imiquimod-induced psoriasis-like dermatitis. The potential therapeutic properties of Grg3 potentially involve modulation of NLRP3 inflammasome activation, suppression of NF-κB signaling, and restoration of Th17/Treg cell homeostasis.